Cutler Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cutler Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,100	Closed	-$2K	–	4201
2023 Q3	$2K	Buy	+2,100	New	+$83.2K	﹤0.01%	3324
2021 Q2	–	Sell	-5,000	Closed	-$1K	–	6214
2021 Q1	$1K	Sell	5,000 -5,000	-50%	-$681K	﹤0.01%	5333
2020 Q4	$37K	Buy	+10,000	New	+$1.19M	﹤0.01%	2222
2018 Q3	–	Sell	-2,000	Closed	-$54K	–	4567
2018 Q2	$54K	Buy	2,000 +1,000	+100%	+$64.6K	﹤0.01%	1561
2018 Q1	$1K	Buy	+1,000	New	+$50.4K	﹤0.01%	4129
2017 Q4	–	Sell	-11,500	Closed	-$3K	–	5730
2017 Q3	$3K	Sell	11,500 -4,200	-27%	-$249K	﹤0.01%	4849
2017 Q2	$26K	Sell	15,700 -30,100	-66%	-$1.81M	﹤0.01%	3147
2017 Q1	$55K	Buy	45,800 +7,100	+18%	+$541K	﹤0.01%	2326
2016 Q4	$203K	Sell	38,700 -6,000	-13%	-$426K	0.01%	1287
2016 Q3	$517K	Buy	+44,700	New	+$2.85M	0.02%	587
2016 Q2	–	Sell	-1,900	Closed	-$4K	–	7164
2016 Q1	$4K	Sell	1,900 -300	-14%	-$19.6K	﹤0.01%	5076
2015 Q4	$32K	Buy	+2,200	New	+$220K	﹤0.01%	2925

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Cutler Group's RARE Position: Q4 2023 in Review

Cutler Group sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2023, closing a stake of 1,010 shares — an estimated $36K sold.

Cutler Group first reported a position in RARE in Q1 2016 and held it in 15 quarters. The position peaked at $753K in Q4 2016. 236 funds tracked by Wall St. Rank hold RARE as of Q4 2023.

Cutler Group reported no remaining Ultragenyx Pharmaceutical position as of Q4 2023 after selling out during the quarter.
Cutler Group sold 1,010 Ultragenyx Pharmaceutical shares in Q4 2023, an estimated $36K.
Cutler Group first reported a position in Ultragenyx Pharmaceutical in Q1 2016 and held it in 15 quarters.
Cutler Group's Ultragenyx Pharmaceutical position peaked at $753K in Q4 2016.
236 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.